EcoR1 Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

EcoR1 Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-519,119	Closed	-$40.6M	–	60
2020 Q2	$40.6M	Buy	519,119 +147,911	+40%	+$9.79M	3%	15
2020 Q1	$16.5M	Buy	371,208 +109,654	+42%	+$5.69M	1.72%	19
2019 Q4	$11.2M	Buy	261,554 +200,000	+325%	+$8.25M	1.01%	23
2019 Q3	$2.63M	Sell	61,554 -436,345	-88%	-$23.7M	0.33%	28
2019 Q2	$31.6M	Hold	497,899	–	–	3.19%	11
2019 Q1	$34.5M	Buy	+497,899	New	+$28.4M	3.18%	12
2018 Q4	–	Sell	-254,000	Closed	-$19.4M	–	59
2018 Q3	$19.4M	Buy	+254,000	New	+$20.7M	1.75%	18

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EcoR1 Capital's RARE Position: Q3 2020 in Review

EcoR1 Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2020, closing a stake of 519,119 shares — an estimated $40.6M sold.

EcoR1 Capital first reported a position in RARE in Q3 2018 and held it in 7 quarters. The position peaked at $40.6M in Q2 2020. 206 funds tracked by Wall St. Rank hold RARE as of Q3 2020.

EcoR1 Capital reported no remaining Ultragenyx Pharmaceutical position as of Q3 2020 after selling out during the quarter.
EcoR1 Capital sold 519,119 Ultragenyx Pharmaceutical shares in Q3 2020, an estimated $40.6M.
EcoR1 Capital first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and held it in 7 quarters.
EcoR1 Capital's Ultragenyx Pharmaceutical position peaked at $40.6M in Q2 2020.
206 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2020.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.